Volume : 12, Issue : 03, March – 2025
Title:
FORMULATION DEVELOPMENT AND EVALUATION OF BUPRANOLOL TRANSDERMAL PATCHES
Authors :
Lal Singh Bariya*, Prithu Pathak, Trapti Shrivastava, Kuldeep Ganju
Abstract :
The present study aimed to develop and evaluate matrix-type transdermal patches of bupranolol using various polymers such as hydroxypropyl methylcellulose (HPMC), Eudragit RLPO, Eudragit RSPO, and ethyl cellulose for sustained drug delivery. Bupranolol, a non-selective β-blocker with a short half-life and low oral bioavailability due to extensive first-pass metabolism, is a suitable candidate for transdermal administration. The patches were prepared using the solvent casting technique with PEG 400 as a plasticizer and methanol/chloroform as solvents. Six formulations (F1–F6) were developed and evaluated for physical parameters including thickness, folding endurance, moisture content, moisture uptake, tensile strength, drug content uniformity, and in vitro drug release. Among the formulations, F4 demonstrated optimal properties, showing high folding endurance (285 ± 6), suitable tensile strength (0.969 ± 0.014 kg/cm²), high drug content (99.45 ± 0.36%), and a sustained drug release of 98.65% over 12 hours. The drug release profile of F4 followed zero-order kinetics (R² = 0.9872), indicating a consistent and controlled release. These results suggest that F4 is a promising formulation for effective transdermal delivery of bupranolol, potentially improving patient compliance and therapeutic outcomes.
Keywords: Bupranolol, Transdermal Patch, HPMC, Eudragit RLPO, Sustained Release, Zero-order Kinetics, Solvent Casting, Drug Delivery System
Cite This Article:
Please cite this article in press Lal Singh Bariya et al., Formulation Development And Evaluation Of Bupranolol Transdermal Patches., Indo Am. J. P. Sci, 2025; 12(05).
Number of Downloads : 10
References:
1. Prausnitz MR, et al. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.
2. Guy RH, et al. Transdermal drug delivery. In: Drug Delivery: Principles and Applications. 2nd ed. Wiley-Interscience; 2010.
3. Schönfeld W, et al. Pharmacokinetics of bupranolol. Eur J Clin Pharmacol. 1974;7(2):113–117.
4. Patel RP, et al. Formulation and evaluation of transdermal patches of curcumin. Int J Pharm Sci Res. 2009;1(1):30–34.
5. Dhawan S, et al. Evaluation of mucoadhesive properties of chitosan microspheres prepared by different methods. AAPS PharmSciTech. 2003;4(4):61–67.
6. Lincy J, Arun K, Sandra S. 2013 2(1). Formulation & evaluation of Amlodipine Transdermal Patches. A research. Int. J. of research of pharmacy, 85-86.
7. Selvam RP, Singh A, Sivakumar T. 2010. Transdermal drug delivery system for anti-diabetic drugs- A review, Int J Pharm and Biom. 15(1):1-13.
8. Izumoto T, Aioi A, Uenoyana S, Kariyama K, Azuma M. Relationship between the transference of drug from a transdermal patch and physicochemical properties, Chem Pharm Bull (Tokyo) 1992; 40: 456- 458.
9. Gibaldi M, Perrier D; Statistical methods for population pharmacokinetic modeling. Drugs and the Pharmaceutical Sciences, 2nd ed., Marcel Dekker, Inc, New York and Basel, 1982.
10. Higuchi T; Mechanism of sustained medication, Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci., 1963; 84: 1464-77.
11. Richard W. Korsmeyer, Robert Gurny, Eric Doelker, Pierre Buri, Nikolaos A. Peppas. Mechanisms of solute release from porous hydrophilic polymers. International Journal of Pharmaceutics. 15(1): 1983; 25-35